论文部分内容阅读
目的:探讨血清金属蛋白酶组织抑制剂-1(TIMP-1)和金属蛋白酶组织抑制剂-2(TIMP-2)水平在晚期非小细胞肺癌(NSCLC)诊断及疗效预后评价中的临床价值。方法:用酶联免疫吸附法(ELISA)检测26名健康人和20例良性肺病患者及82例晚期NSCLC患者化疗前后血清TIMP-1、TIMP-2水平,并作对比分析。结果:NSCLC组化疗前血清中TIMP-1、TIMP-2水平均明显高于健康组(P<0.01)和良性肺病组(P<0.05)。NSCLC患者化疗有效组在化疗结束后7 d的血清TIMP-1、TIMP-2水平明显低于化疗前,P<0.01;化疗无效组化疗前、后血清TIMP-1、TIMP-2水平差异无统计学意义,P>0.05。单因素生存分析提示,血清TIMP-1水平与晚期NSCLC患者的预后有关,P<0.05。结论:NSCLC患者血清TIMP-1水平是一个有价值的肿瘤标志和预后指标,检测化疗前后血清TIMP-1、TIMP-2水平对评估化疗疗效有一定的临床意义。
Objective: To investigate the clinical value of serum levels of TIMP-1 and TIMP-2 in the diagnosis and prognosis of advanced non-small cell lung cancer (NSCLC). Methods: The levels of TIMP-1 and TIMP-2 in serum of 26 healthy people, 20 patients with benign lung disease and 82 patients with advanced NSCLC before and after chemotherapy were detected by enzyme linked immunosorbent assay (ELISA). Results: The levels of TIMP-1 and TIMP-2 in NSCLC group were significantly higher than those in healthy group (P <0.01) and benign lung disease group (P <0.05). The levels of serum TIMP-1 and TIMP-2 in chemotherapy-effective group of NSCLC patients at 7 d after chemotherapy were significantly lower than those before chemotherapy (P <0.01). There was no statistical difference in the levels of TIMP-1 and TIMP-2 before and after chemotherapy Significance of learning, P> 0.05. Univariate survival analysis suggested that serum TIMP-1 level correlated with the prognosis of patients with advanced NSCLC (P <0.05). Conclusion: The serum level of TIMP-1 in NSCLC patients is a valuable tumor marker and prognostic indicator. Detecting the serum levels of TIMP-1 and TIMP-2 before and after chemotherapy have some clinical significance in evaluating the curative effect of chemotherapy.